Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 5/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385376 | 0.90 | NT5E (0.49) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5385382 | 0.90 | NT5E (0.49) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5396369 | 0.88 | ADORA1 (0.50) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5401465 | 0.88 | ADORA1 (0.50) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL14593744 | 0.88 | ADORA1 (0.50) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL31734847 | 0.82 | ADORA3 (0.72) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5409612 | 0.78 | ADORA1 (0.63) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5395711 | 0.78 | ADORA1 (0.46) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL14593749 | 0.78 | ADORA1 (0.46) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5395722 | 0.78 | ADORA1 (0.46) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163928-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1590359-A2 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV Therapeutics Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6946272-B1 | Transition state analogs | PROTEINIX CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004069185-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-5952462-A | Transition state analogs | IGEN INTERNATIONAL INC. (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | NT5E 294/4885ADORA3 3/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.